Literature DB >> 27558441

Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.

Chao Wang1,2, Wujin Sun1,2, Grace Wright1,2, Andrew Z Wang1,2,3, Zhen Gu4,5,6.   

Abstract

Inflammation-triggered combination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CpG; anti-PD1; cancer immunotherapy; drug delivery; nanobiotechnology

Mesh：

Substances：

Year:  2016        PMID： 27558441      PMCID： PMC5283805          DOI： 10.1002/adma.201506312

Source DB:  PubMed          Journal:  Adv Mater        ISSN： 0935-9648            Impact factor:   30.849


  50 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.

Authors:  Elizabeth I Buchbinder; F Stephen Hodi
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

Review 3.  Nanomaterials. Programmable materials and the nature of the DNA bond.

Authors:  Matthew R Jones; Nadrian C Seeman; Chad A Mirkin
Journal:  Science       Date:  2015-02-20       Impact factor: 47.728

Review 4.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 7.  Metastasis as an evolutionary process.

Authors:  Samra Turajlic; Charles Swanton
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

Review 8.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 9.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

Authors:  Thomas F Gajewski; Seng-Ryong Woo; Yuanyuan Zha; Robbert Spaapen; Yan Zheng; Leticia Corrales; Stefani Spranger
Journal:  Curr Opin Immunol       Date:  2013-04-08       Impact factor: 7.486

Review 10.  The effects of surgery on tumor growth: a century of investigations.

Authors:  R Demicheli; M W Retsky; W J M Hrushesky; M Baum; I D Gukas
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976
View more
  49 in total

Review 1.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

Review 2.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

Review 3.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 4.  Nanomedicine and macroscale materials in immuno-oncology.

Authors:  Qingxue Sun; Matthias Barz; Bruno G De Geest; Mustafa Diken; Wim E Hennink; Fabian Kiessling; Twan Lammers; Yang Shi
Journal:  Chem Soc Rev       Date:  2019-01-02       Impact factor: 54.564

Review 5.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

Review 6.  Recent advances in sonodynamic immunotherapy.

Authors:  Hui Wang; Guo-Qing Sui; Zhi-Xia Sun; Jia-Rui Du; Yang Wang; Zong-Hua Yue; Han-Yu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-13       Impact factor: 4.322

7.  A m6A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.

Authors:  Mengyuan Lei; Chenghan Luo; Jiayang Zhang; Wenjun Cao; Jian Ge; Min Zhao
Journal:  Cell Oncol (Dordr)       Date:  2022-08-15       Impact factor: 7.051

8.  Local delivery of checkpoints antibodies.

Authors:  Chao Wang; Yanqi Ye; Zhen Gu
Journal:  Hum Vaccin Immunother       Date:  2016-09-26       Impact factor: 3.452

9.  One-Pot Synthesis of Multiple Protein-Encapsulated DNA Flowers and Their Application in Intracellular Protein Delivery.

Authors:  Eunjung Kim; Limor Zwi-Dantsis; Natalie Reznikov; Catherine S Hansel; Shweta Agarwal; Molly M Stevens
Journal:  Adv Mater       Date:  2017-05-05       Impact factor: 30.849

10.  Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles.

Authors:  Kyle M Garland; Sema Sevimli; Kameron V Kilchrist; Craig L Duvall; Rebecca S Cook; John T Wilson
Journal:  Cell Mol Bioeng       Date:  2019-05-03       Impact factor: 2.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.